LRP1 and atherosclerosis: In the context of atherosclerosis, loss of macrophage LRP1 conferred resistance to the TNFα-inhibitor adalimumab, and enhanced plaque cellularity and inflammation, suggesting that the anti-atherosclerotic effects of TNFα blockade may be dependent on the presence of macrophage LRP1 (65).